Reported Saturday, Pfizer's Berobenatide Achieves 15.9% Weight Loss At 32 Weeks With No Plateau In VESPER-1 As Monthly GLP-1 Phase 3 Program Advances

Loading news article.

Reported Saturday, Pfizer's Berobenatide Achieves 15.9% Weight Loss At 32 Weeks With No Plateau In VESPER-1 As Monthly GLP-1 Phase 3 Program Advances | WAPE

Reported Saturday, Pfizer's Berobenatide Achieves 15.9% Weight Loss At 32 Weeks With No Plateau In VESPER-1 As Monthly GLP-1 Phase 3 Program Advances

Article summary

Related companies

Comments —